Impact of Atogepant on Migraine Headache Severity for the Preventive Treatment of Episodic Migraine: A Post-Hoc Analysis of the 12-Week ADVANCE and 52-Week Open-Label Trials (P9-12.003)
Evaluate the impact of atogepant 60mg once daily (QD) on migraine headache day severity in participants with episodic migraine (EM).
Authors
- Teshamae Monteith (ORCID: https://orcid.org/0000-0001-8912-252X)
- Brett Dabruzzo (ORCID: https://orcid.org/0009-0008-3048-2633)
- Belinda Savage‐Edwards
- Hsiangkuo Yuan (ORCID: https://orcid.org/0000-0002-4536-9974)
- Yingyi Liu (ORCID: https://orcid.org/0009-0002-5243-0793)
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Umer Najib (ORCID: https://orcid.org/0000-0002-1116-9229)
- Natty Chalermpalanupap
- Ivonna Reda
Institutions
- University of Miami (US)
- MedStar Georgetown University Hospital (US)
- West Virginia University Hospitals (US)
- AbbVie (United States) (US)
- Headache Care Center (US)
- AbbVie (Japan)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208472
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00